Proteomics

Dataset Information

0

Coordinate β-adrenergic inhibition of mitochondrial activity and angiogenesis arrest tumor growth


ABSTRACT: Mitochondrial metabolism has emerged as a promising target against the mechanisms of tumor growth. Herein, we have screened an FDA-approved library to identify drugs that inhibit mitochondrial respiration. The β1-blocker nebivolol specifically hinders oxidative phosphorylation in cancer cells by concertedly inhibiting Complex I and ATP synthase activities. Complex I inhibition is mediated by interfering the phosphorylation of NDUFS7. Inhibition of the ATP synthase is exerted by the overexpression and binding of the ATPase Inhibitory Factor 1 (IF1) to the enzyme. Remarkably, nebivolol also arrests tumor angiogenesis by arresting endothelial cell proliferation. Altogether, targeting mitochondria and angiogenesis triggers a metabolic and oxidative stress crisis that restricts the growth of colon and breast carcinomas. Nebivolol holds great promise to be repurposed for the treatment of cancer patients.

INSTRUMENT(S): LTQ Orbitrap Velos

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Permanent Cell Line Cell, Cell Culture

DISEASE(S): Colon Cancer

SUBMITTER: Cristina Nuevo Tapioles  

LAB HEAD: José M. Cuezva

PROVIDER: PXD019750 | Pride | 2020-06-28

REPOSITORIES: Pride

Dataset's files

Source:
Action DRS
210918_CNuevo_NEB_Todo.mgf Mgf
210918_HCT116_NEB_Todo.raw Raw
250918_CNuevo_Control_Todo.mgf Mgf
250918_HCT116_Control_Todo.raw Raw
peptidescrl_1_1_0.mzid.gz Mzid
Items per page:
1 - 5 of 6

Similar Datasets

2019-11-04 | PXD014475 | Pride
2024-04-11 | PXD050718 | Pride
2024-05-15 | PXD050765 | Pride
2024-01-26 | PXD041119 | Pride
2022-09-26 | PXD035978 | Pride
2021-05-24 | PXD020262 | Pride
2024-06-23 | PXD052306 | Pride
2019-07-15 | PXD013482 | Pride
2020-05-26 | PXD012799 | Pride
2022-10-25 | PXD029136 | Pride